A number of other firms have also recently commented on TZYM. Analysts at Canaccord Genuity downgraded shares of Tranzyme from a ?buy? rating to a ?hold? rating in a research note to investors on Friday, November 16th. Separately, analysts at BMO Capital Markets downgraded shares of Tranzyme from an ?outperform? rating to a ?market perform? rating in a research note to investors on Friday, November 16th. They now have a $1.00 price target on the stock, down previously from $6.00. Finally, analysts at Stifel Nicolaus downgraded shares of Tranzyme from a ?buy? rating to a ?hold? rating in a research note to investors on Thursday, November 15th.
Shares of Tranzyme traded down 3.81% during mid-day trading on Wednesday, hitting $0.5196. Tranzyme has a 52 week low of $0.53 and a 52 week high of $5.64. The stock?s 50-day moving average is currently $0.97. The company?s market cap is $14.3 million.
Tranzyme last released its earnings data on Thursday, November 8th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.29) by $0.13. The company had revenue of $1.80 million for the quarter, compared to the consensus estimate of $1.99 million. Analysts expect that Tranzyme will post $-0.95 EPS for the current fiscal year.
Tranzyme, Inc. is a clinical-stage bio-pharmaceutical company focused on discovering, developing and commercializing small molecule therapeutics for the treatment of acute (hospital-based) and chronic GI motility disorders. To view Zacks? full report, visit www.zacks.com
Stay on top of analysts’ coverage with American Banking & Market News’ that provides a concise list of analysts’ upgrades, analysts’ downgrades and analysts’ price target changes for each day..